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Abstract
The role of Sirtuin 6 (SIRT6) as a tumor suppressor or oncogene in liver cancer remains
controversial. Thus, we identified the specific role of SIRT6 in the progression of hepatocel-
lular carcinoma (HCC). SIRT6 expression was significantly higher in HCC cell lines and
HCC tissues from 138 patients than in an immortalized hepatocyte cell line, THLE-2 and
non-tumor tissues, respectively. SIRT6 knockdown by shRNA suppressed the growth of
HCC cells and inhibited HCC tumor growth in vivo. In addition, SIRT6 silencing significantly
prevented the growth of HCC cell lines by inducing cellular senescence in the p16/Rb- and
p53/p21-pathway independent manners. Microarray analysis revealed that the expression
of genes involved in nucleosome assembly was apparently altered in SIRT6-depleted
Hep3B cells. SIRT6 knockdown promoted G2/M phase arrest and downregulation of genes
encoding histone variants associated with nucleosome assembly, which could be attributed
to DNA damage. Taken together, our findings suggest that SIRT6 acts as a tumor promoter
by preventing DNA damage and cellular senescence, indicating that SIRT6 represents a
potential therapeutic target for the treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is a major histological subtype, accounting for 85–90% of
primary liver cancers[1]. Incidence rates of HCC have remained high in Eastern and South-
Eastern Asia and have increased in the United States and Central Europe[2]. Although great
efforts have beenmade to improve the treatment of HCC in the past decade, advanced HCC
often has a poor prognosis due to chemotherapeutic resistance and the limited applicability of
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surgical resection and liver transplantation. Therefore, understanding the precise mechanisms
underlying HCC progression and identifying novel therapeutic targets are crucial for the effec-
tive treatment of HCC.
Sirtuins are a family of NAD+-dependent deacylases and have been implicated in diverse
biological processes and various diseases, including cancer. SIRT6, one of sirtuins, regulates
DNA repair, cell metabolism, and transcription by targeting diverse substrates for deacetyla-
tion or ADP-ribosylation[3]. SIRT6 is involved in base excision repair or DNA double-strand
break (DSB) repair and required for maintaining genomic stability[4]. SIRT6 functions as a
histone H3K9Ac deacetylase to repress the transcriptional activities of target genes involved in
apoptosis, inflammation, and metabolism[5]. Crucial roles of SIRT6 in DNA repair, metabo-
lism, and inflammation which are associated with cancer have prompted much investigation
into the role of SIRT6 in cancer progression. However, the role and mechanistic function of
SIRT6 remain elusive in carcinogenesis.
The role of SIRT6 in cancer remains controversial. Contradictory findings as to whether
SIRT6 is a tumor repressor or tumor promoter have been reported, even in the same tissue,
such as the pancreas[6, 7] or breast[8, 9]. SIRT6 expression is lower in human pancreatic can-
cer than in healthy tissue[6]. In this context, low levels of SIRT6 upregulated the transcriptional
activity of HIF1 and Myc, resulting in accelerated glycolysis and proliferation, respectively[6].
However, another study showed that inhibiting SIRT6 reduced the viability of Capan-1 pancre-
atic cancer cells treated with gemcitabine, demonstrating the oncogenic potential of SIRT6[10].
In breast cancer, contradictory roles of SIRT6 in drug sensitivity have been reported. The
knockdown of SIRT6 increased tumorigenesis and trastuzumab resistance in breast cancer[11]
while sensitizing cells to paclitaxel and epirubicin[12].
The reported functions of SIRT6 in liver cancer have also been inconsistent. SIRT6 sup-
pressed the initiation of liver cancer by inhibiting survivin expression in a liver cancer mouse
model[13]. SIRT6 expression was lower in cirrhotic and HCC tissues than in normal liver tis-
sues according to a publically available cancer microarray dataset[14]. However, SIRT6 overex-
pression prevented apoptosis by suppressing BCL2-associatedX protein expression,
demonstrating the oncogenic potential of SIRT6 in HCC[15]. Furthermore, SIRT6 expression
was high in HCC tissues and correlated with poor prognosis[15]. This controversy over the
function of SIRT6 in HCC prompted us to investigate the roles and mechanism of SIRT6 in the
progression of HCC.
We found that SIRT6 was upregulated more in HCC cell lines and human HCC tissues than
in an immortalizedhepatocyte cell line and normal tissues, respectively. SIRT6 silencing by
shRNA significantly downregulated the growth of HCC cells by inducing cellular senescence in
the p16/Rb- and p53/p21-pathway independentmanners. SIRT6 knockdown promoted G2/M
phase arrest and downregulation of genes encoding histone variants associated with nucleo-
some assembly, which could be attributed to DNA damage. Our study provides evidence that
SIRT6 promotes HCC by preventing cellular senescence induced by DNA damage. These find-
ings suggest that SIRT6 represents a promising therapeutic target for HCC treatment.
Materials and Methods
Cell culture
Cell lines, SNU449, SNU475, Huh7 and Hep3B were purchased from the Korean Cell Line
Bank (Korea). The cells were cultured at 37°C under 5% CO2 in DMEM supplemented with
10% FBS, 100 units/ml of penicillin and 100 μg/ml streptomycin. THLE-2 cell line was pur-
chased from the American Type Culture Collection (USA). THLE-2 cells originated from
human primary normal liver cells were plated on culture plates pre-coated with a solution
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containing 0.01 mg/mL fibronectin, 0.03 mg/mL bovine collagen type I and 0.01 mg/mL bovine
serum albumin dissolved in Bronchial Epithelium Basal Medium (BEBM, Lonza). THLE-2
cells were cultured at 37°C under 5% CO2 in BEBM supplemented with BEGM SingleQuots
(Lonza).
Cell transfection
To deplete SIRT6 in HCC cells, lentiviral infectionwas performed as describedpreviously[16].
Briefly, control and SIRT6-depleted cell lines were established utilizing lentivirus particles con-
taining non-target shRNA (SHC016V) and SIRT6-target shRNA (SHCLNV-NM_016539)
which were purchased from Sigma (USA). HCC cells were seeded onto plates and infected with
lentiviral particles in DMEM containing 8 μg/ml polybrene (Sigma). One day after the incuba-
tion, the medium containing lentivirus was changed with the growth medium, and the cells
were incubated for another day. Puromycin (Invitrogen) at 2 μg/ml was added to each well to
select for cells efficient for SIRT6 depletion. The target sequences of the five shRNA clones are
shown in S1 Table.
Reagent and WST-1 assay
Doxorubicin and etoposide were purchased from Calbiochem (USA) and Sigma (USA), respec-
tively. The effects of those compounds on HCC cell viability were assessed by theWST-1 assay.
Cells were incubated with the culture medium containing theWST-1 reagent (Roche) with 1/
10 dilution for 48 h after drug treatments. After incubating cells for 1 hr 40 min at 37°C under
5% CO2, the absorbance at 450 nm was measured using a microplate reader (Spectrafluor Plus,
Tecan).
Western blotting
Western blotting was performed as describedpreviously[17]. The list of antibodies used for
western blotting are shown in S2 Table.
Colony formation assay
Lentivirus infected cells were plated onto six-well dishes (500 cells per well), and cultured in
the growth medium containing 2 μg/ml puromycin for 15 days. The media was replaced with
fresh media every three days. The cells were fixed with 4% formaldehyde in PBS and stained
with 0.5% crystal violet in 25% methanol for 1 hr. Plates were then washed with PBS to remove
excessive dye and photographed with a digital camera. Clonogenicity was quantified by mea-
suring the absorbance of crystal violet at 595 nm after extracting it with 20% acetic acid.
Soft agar assay
The agar base layer (0.5% agar with the growth medium) was covered in 6-cm plates. A top
layer containing 25×103 cells was suspended in 0.35% agarose containing the growth medium
and put on top of the base layer. After 5 min, the growth mediumwas added to prevent agarose
gel from drying.Cells were fixed and stained with 4% paraformaldehyde for 20 min and 3.2%
crystal violet, respectively, when the size of colonies between two groups was obviously differ-
ent for Hep3B at the day 16 and for Huh-7 at the day 19.
Xenograft assay
Five-week-old male nude mice were obtained fromOrient Bio (Korea) and raised in a specific
pathogen-free room within the animal facilities at POSTECH (Korea). The nude mice were
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handled according to the “Institutional Animal Care and Use” guidelines of POSTECH. The
protocol was approved by the POSTECH Institutional Animal Care and Use Committee of
POSTECH. (Permit Number: 2014-02-0011A1). All tumors were obtained after cervical dislo-
cation was performed, and all efforts were made to minimize suffering. Hep3B cells were
infected with lentiviral particles containing either control shRNA or SIRT6-shRNA clone 1 or
3. Four days after viral transduction, infected cells (1 x 106) were resuspended in 100 μl serum-
free DMEMwith the Matrigel basement membrane matrix (BD biosciences) at a 1:1 volume
ratio and subcutaneously injected into the right back of the mice. Mice were monitored three
times weekly and then daily as their volumes approached 200 mm3. General appearance, activ-
ity level and body weight were monitored to check the status of health. No mice became
severely ill or died at prior to the experimental end point. Tumor sizes were measured every 4
days from 2 weeks after inoculation using a Vernier caliper. Tumor volumes were assessed
according to the formula L x S2 x 0.52, where L is the longest diameter and S the shortest diam-
eter of the tumor. End point was set to the day whenmaximum size of control tumor was
about 15 mm in diameter. Maximum tumor sizes of each group at the endpoint were 693.1
mm3, 302.1 mm3 and 376.5 mm3The mice were sacrificedby cervical dislocation 38 days after
injection and solid tumors were isolated. All tumors were obtained after cervical dislocation
was performed, and all efforts were made to minimize suffering.
Immunofluorescence
To confirmKi-67 positive cells in the tumor section, solid tumors frommice were placed in
formalin for paraffin block preparation. The tumor sections were incubated with mouse anti-
Ki-67 antibody (S2 Table) diluted in PBS containing 10% horse serum. Sections were then
washed with PBS containing 0.05% Tween-20 and incubated with anti-rabbit Alexa Fluor 594
(Invitrogen) which as diluted in PBS containing 10% horse serum for 1 hr at room temperature
in the dark. Sectionswere then washed with PBS containing 0.05% Tween-20, incubated with
Hoechst 33342 (Invitrogen) for 10 min in the dark and mounted with Mounting medium
(Dako). To verify γH2AX foci in Hep3B cells, immunocytochemistrywas performed as
describedpreviously[17]. Following antibodies were used for immunofluorescent staining:
anti-γH2AX antibody (S2 Table) and anti-rabbit Alexa Fluor 594 (Invitrogen).
β-galactosidase senescence assay
After washed in PBS, cells were fixed for 5 min in PBS containing 2% formaldehyde and 0.2%
glutaraldehyde. Subsequently cells were incubated with the β-galactosidase staining solution
(40 mM citric acid, 5 mMK4[Fe(CN)6]3H2O, 5 mMK3[Fe(CN)6], 150 mMNaCl, 2 mM
MgCl2 and 1 mg/ml X-galactosidase) for 5 hrs at 37°C.
Microarray analysis
The synthesis of target cRNA probes and hybridization were performed using the Agilent’s
Low RNA Input Linear Amplification kit (Agilent Technology, USA) according to the manu-
facturer’s instructions. Briefly, each one μg of total RNA and the T7 promoter primer was
mixed and incubated at 65°C for 10 min. The cDNA master mix (5X First strand buffer, 0.1 M
DTT, 10 mM dNTPmix, RNase-Out, and MMLV-RT) was prepared and added to the reaction
mixer. The samples were incubated at 40°C for 2 hrs and then the dsDNA synthesis was termi-
nated by incubating at 65°C for 15 min. The transcriptionmaster mix (4X Transcription buffer,
0.1MDTT, NTP mix, 50% PEG, RNase-Out, Inorganic pyrophosphatase, T7-RNA polymer-
ase, and Cyanine 3/5-CTP) was prepared as directed by the manufacturer. Transcription of
dsDNA was performed by adding the transcriptionmaster mix to the dsDNA reaction samples
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and then incubating at 40°C for 2 hrs. Amplified and labeled cRNA was purified by a cRNA
Cleanup Module (Agilent Technology) according to the manufacturer’s protocol. Labeled
cRNA target was quantified using a spectrophotometer (ND-1000, NanoDrop Technologgy,
USA). After checking labeling efficiency, fragmentation of cRNA was performed by adding the
10X blocking agent and the 25X fragmentation buffer, and then incubating at 60°C for 30 min.
The fragmented cRNA was resuspendedwith the 2X hybridization buffer and directly pipetted
onto the assembled Agilent’s Human OligoMicroarray (44K). The arrays hybridized at 65°C
for 17 hrs using a hybridization oven (Agilent Technology, USA). The hybridizedmicroarrays
were washed as directed by the manufacturer.
Data acquisition and analysis
The hybridized images were scanned using a DNA microarray scanner and quantified with the
Feature Extraction Software (Agilent Technology, USA). All data normalization and selection
of fold-changed genes were carried out using a software, GeneSpringGX 7.3 (Agilent Technol-
ogy, USA). The averages of normalized ratios were determined by calculating the average of
normalized signal channel intensity divided by the average of normalized control channel
intensity. Functional annotation of genes was made according to the procedures of Gene
Ontology TM Consortium (http://www.geneontology.org/index.shtml) utilizing the Gene-
SpringGX 7.3. Gene classification was based on searches done by DAVID (http://david.abcc.
ncifcrf.gov/). Data were deposited in the GEO database (http://www.ncbi.nlm.nih.gov/geo/,
accession number: GSE75905).
Cell cycle analysis
To analyze the progression of cell cycle, 1x105 Hep3B cells were seeded onto 6-well plates and
transfected with lentivirus containing negative control or SIRT6 shRNA. Four days after incu-
bation, cells were collected after trypsinization, fixed in the fixation solution containing 70%
ethanol and 0.5% Tween-20, washed in PBS containing 1% BSA, resuspended in 200 μl PBS
containing 100 μg/ml RNase (Sigma) and 50 μg/mL propidium iodide (Sigma), incubated in
the dark for 40 min at room temperature, and then analyzed using a flow cytometer (Canto II,
BD Biosciences). Acquired data were analyzed using the ModFit LT software (Verity Software
House).
Bromodeoxyuridine (BrdU) incorporation assay
BrdU incorporation assays were conducted in Hep3B cells to estimate DNA replication. Cells,
transfected by the respective lentiviruses containing NC and shSIRT6, were incubated in the
presence of 10μM BrdU (BD Pharmingen) for 2hours. Cells were then fixed in ethanol, dena-
tured with 2N HCl containing 0.5% Triton X-100, and stained with AlexaFluor647-conjugated
anti-BrdU antibody (Invitrogen). Samples were analyzed using both LSR FortessaTM and
FlowJo software (Becton-Dickinson,Mississauga, Canada)
Tissue samples from patients
HCC (n = 115) and surrounding non-tumor hepatic tissues (n = 48) were obtained from 138
HCC patients who had undergone curative resection for primaryHCC between 1995 and 2007
at the Ajou Medical Center in Korea. Fresh tumors and surrounding normal tissues were partly
snap-frozen in liquid nitrogen immediately after hepatectomy and stored at −80°C. Tissues
used in the study were obtained from the patients with written informed consent for the
human subjects research; all the potential participants subjected to hepatectomy were given the
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written form for informed consent to allow them to decide whether or not they want to partici-
pate in the study. The informed consent documents signed by the participants at the time of
tissue donation have been deposited after the consent procedure and study protocol were
approved by the Institutional ReviewBoard of the Ajou Medical Center.
Real-time RT-PCR
SIRT6 mRNA levels in tumor and non-tumor tissues were determined by real-time RT-PCR as
describedpreviously[18]. The mRNA levels of SIRT6 was normalized relative to a set of refer-
ence genes including SDHA, HPRT1, HMBS, GAPDH and B2M by subtracting the average
expression levels of the five reference genes as an internal control. The mRNA expression levels
were calculated as 2-ΔCT utilizingΔCT values (CT of SIRT6 –average CT of reference genes).
The primer and probe sequences are shown in S3 Table. mRNA levels of genes regulated by
SIRT6 in Hep3B cells were measured similarly by real-time RT-PCR as describedpreviously
[16]. The primer sequences are shown in S4 Table. The relative mRNA levels of target genes
were determined by the 2-ΔΔCT method.
Statistical analysis
The Box andWhisker plots were used to compare mRNA levels of SIRT6 (2−ΔCt values)
between tumors and non-tumors, and differences assessed by Student’s t test. Results from col-
ony forming assays, weights of tumors, immunofluorescence intensities and theWST-1 assay
were compared with by bar graphs after analyzed by Student’s t test. P values< 0.05 were con-
sidered statistically significant, and data marked with a single (), two () or three () aster-
isks for P values< 0.05,< 0.01 and< 0.001, respectively. Statistical analyses were performed
with SPSS v. 18.0 (IBM) and the open source statistical program R v 3.1.1.
Results
SIRT6 knockdown inhibits HCC cell growth in vitro
In order to investigate the role of SIRT6 in liver cancer, the protein levels of SIRT6 were com-
pared among an immortalizedhepatocyte cell line, THLE-2, and such six HCC cell lines as
Hep3B, HepG2, SNU475, SK-Hep1, SNU449 and Huh-7. SIRT6 levels were higher in liver can-
cer cells than THLE-2 cells (Fig 1A and 1B). SIRT6 mRNA levels were also measured by
RT-PCR in 115 HCC and 48 non-tumor specimens fromHCC patients. SIRT6 mRNA levels
were significantly elevated in tumor tissues compared with those in non-tumor tissues (Fig 1C;
0.0167 versus 0.039; mean 2−ΔCT values, P< 2.2E−16). To investigate the effect of SIRT6 on
HCC cell growth, SIRT6 was silenced by shRNA and colony formation assays were then per-
formed. Efficient silencing of SIRT6 was confirmed by western blotting, and lentiviral particles
targeting five different sequences showed different knockdown efficiencies (Fig 1D). Clones 1
and 3 showed the most efficient knockdown in HCC cells. SIRT6 knockdown reduced the col-
ony-forming abilities of Hep3B (shSIRT6-1 and -3 by 29.0 ± 4.8% and 46.2 ± 6.6%, respec-
tively), Huh-7 (shSIRT6-1 and -3 by 27.1 ± 0.5% and 26.0 ± 4.2%, respectively), SNU475
(shSIRT6-1 and -3 by 35.3 ± 5.7% and 54.4 ± 4.5%, respectively), and SNU449 (shSIRT6-1 and
-3 by 22.7 ± 3.5% and 37.8 ± 4.0%, respectively;P<0.001) cells (Fig 1D and 1E). Anchorage-
independent growth is another indicator of tumorigenicity. We tested the anchorage-indepen-
dent growth of SIRT6-deficient cells in soft agar. SIRT6-deficient Hep3B and Huh-7 cells
showed significantly lower clonogenicity in soft agar than control cells (Fig 1F and 1G;
P<0.01).
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Recently, SIRT6 mutations were found in several tumor types such as non-small-cell lung
cancer, renal clear cell carcinoma, cervical carcinoma, and melanoma[19]. Since naturally
occurring tumor-associated mutations in SIRT6 were shown to alter its stability, localization,
and/or enzymatic activity[19], we checked SIRT6 status in HCC tissues and cell lines using sev-
eral public databases such as COSMIC (Catalogue of Somatic Mutations in Cancer, http://
cancer.sanger.ac.uk/cosmic) and Cancer Genome Atlas (https://tcga-data.nci.nih.gov/docs/
publications/tcga/). Regarding HCC cell lines used for our experiments,mutation status of
SK-Hep1 Huh-7, SNU475 and SNU449 could be obtained from COSMIC. Any SIRT6 muta-
tion was not found in these cell lines. In addition, based on databases of COSMIC and Cancer
Genome Atlas, only three mutations were found among 1,703 tested samples (mutation rate,
0.17%) and 373 tested samples (mutation rate, 0.8%), respectively. We also confirmed that
SIRT6 mutations did not occur in 27 (SIRT6 mutation rate, 0%) and 231 (SIRT6 mutation rate,
0%) HCC samples from two publications published by Japaneses[20] and Korean group[21]
that provided whole-genome sequencing of HCC samples.
Depletion of SIRT6 suppresses tumor growth in a xenograft mouse
model
To investigate the effect of SIRT6 knockdown on tumor growth in vivo, SIRT6-depleted Hep3B
cells were inoculated into the flanks of nude mice. Tumor volumes were measured at the indi-
cated time points (Fig 2A). Significant differences in tumor volumes were observed at 22 days
post-injection between SIRT6-depleted HCC cells and control HCC cells (P<0.05; Fig 2A).
Tumor volumes at endpoint for negative control and SIRT6-depleted tumors were 426.7 ± 60.9
mm3, 214.7 ± 33.3 mm3 and 240.5 ± 42.6 mm3, respectively (Fig 2A). After 38 days, mice were
sacrificed and solid tumors were removed (Fig 2B and 2C). The weights of SIRT6-depleted
tumors (42.0 ± 12.6 mg and 78.6 ± 23.7 mg for shSIRT6-1 and -3, respectively) were lower
than those of tumors without SIRT6-deletion (159.1 ± 43.7 mg; Fig 2D). Proliferating cells in
the excised tumors were quantified by counting the number of Ki-67-positive cells; fewer Ki-
67-positive cells were observed in SIRT6-depleted tumors (shSIRT6-1: 13.8 ± 1.1%, P<0.01;
shSIRT6-3: 19.2 ± 5.1, P<0.05) than in tumors without SIRT6-depletion (30.1 ± 3.3%).
SIRT6 silencing induces cellular senescence in the p16/Rb and p53/
p21-pathway independent manners
Next, the nature of growth inhibition induced by SIRT6 deletion was investigated. SIRT6-si-
lenced cells were flattened and larger (Fig 3A) with the characteristicmorphology of cellular
senescence[17]. ß-gal assays were performed to confirm the induction of cellular senescence by
Fig 1. Effects of SIRT6 depletion on HCC cell growth. (A) The expression of SIRT6 in HCC cell lines and normal liver lysate was
assessed by western blotting using actin as a loading control. (B) Band intensities were measured by densitometry using Image J.
SIRT6 band intensities were normalized to those of actin. (C) Upregulation of SIRT6 mRNA was assessed in HCC tumors relative to
normal adjacent tissues by RT-PCR. (D) Hep3B, Huh-7, SNU475, and SNU449 cells were incubated with lentiviral particles containing
plasmids with either negative control (NC) or SIRT6 shRNA. Five different lentiviral particles (C1–C5) targeting different sequences
were used to delete the SIRT6 gene. HCC cells were harvested 5 days after viral transduction, followed by western blotting to compare
the knockdown efficiency of SIRT6. (E) HCC cells transduced by lentiviral particles were seeded into 6-well plates at a density of 500
cells per well. Transduced HCC cells were selected in the growth medium supplemented with 2 μg/ml of puromycin. Cells were fixed
and stained with crystal violet after 15 days. Representative images of plates were obtained using a digital camera. (F) The dye was
extracted from stained colonies by 20% acetic acid to quantify the colony-forming ability; the extracted dye was quantified by
measuring the absorbance at 595 nm with the percentage of the absorbance being calculated relative to that of NC (100%). (G) Hep3B
and Huh-7 cells, transduced by the respective lentiviruses containing NC and shSIRT6, were cultured in soft agar with DMEM for 16
and 19 days, respectively. The representative micrographs were obtained using the iSolution Lite program. (H) Colonies larger than
the indicated bar on the colony image were counted. The number of colonies (%) was calculated relative to that of NC, which was set
to 100%. All data are representative of three independent experiments. (**P<0.05; ***P<0.001).
doi:10.1371/journal.pone.0165835.g001
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Fig 2. Effect of SIRT6 depletion on tumor growth in a xenograft mouse model (A) Hep3B cells were transduced with a
lentiviral vector containing NC- or SIRT6-shRNA sequences. Hep3B cells were harvested 4 days after viral transduction, and
1 × 106 cells were subcutaneously injected into mice. Tumor sizes in 21 mice were measured every 4 days after the injection
and are shown as means ± SEM. (B) Photographs of mice injected with Hep3B cells were taken after sacrifice. (C) Tumors
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were obtained from the sacrificed mice, and their sizes were compared. (D) Tumor weights from sacrificed mice are shown as
means ± SEM. (E) The expression of Ki-67 was immunohistochemically examined by confocal microscopy, and Ki-67-positive
cells were counted in randomly obtained images. The scale bar indicates 50 μM. (*P<0.01, **P<0.05).
doi:10.1371/journal.pone.0165835.g002
Fig 3. Induction of cellular senescence by SIRT6 depletion in the p16/Rb and p53/p21- independent manners (A) Representative
micrographs of Hep3B cells 6 days after infection with lentiviruses containing NC or shSIRT6. The scale bar indicates 20 μM. (B) Representative
micrographs of SA-ß-gal staining in NC and shSIRT6-depleted Hep3B and Huh-7 cells. The percentage of SA-ß-gal-positive cells was quantified
from 6 different areas in the plate. (C) mRNA levels of the selected cytokine genes in control and SIRT6-silenced Hep3B cells are indicated in the
histogram. (D) The expression of p16, Rb, p53, and p21 was analyzed by western blotting. Three independent experiments were performed.
(**P<0.01).
doi:10.1371/journal.pone.0165835.g003
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SIRT6 deletion. The percentages of SIRT6-depleted HCC cells positively stained with SA-ß-gal
were 29.1 ± 4.9% (shSIRT6-1) and 16.2 ± 8.4% (shSIRT6-3) Hep3B cells and 29.3 ± 5.2%
(shSIRT6-1) and 17.1 ± 6.3% (shSIRT6-1) Huh-7 cells, while that of control HCC cells posi-
tively stained with SA-ß-gal was less than 1.0% Hep3B cells and 6.1% Huh-7 cells (Fig 3B).
Since senescent cells secrete interleukins and cytokines[22], expression levels of several cyto-
kines such as IL8, CXCL1, CXCL2 and CXCL3 were assessed by RT-PCR to validate induction
of senescence. SIRT6 silencing increasedmRNA levels of IL8, CXCL1, CXCL2 and CXCL3 (Fig
3C). The p53/p21- and p16/Rb-axes are the major senescence-triggeringmolecular pathways
[23], so the expression levels of p53, p21, p16, and Rb were assessed. In Hep3B cells, Rb, p53,
and p21 were not detected and p16 expression was not affected by SIRT6 depletion (Fig 3D).
In Huh-7 cells, p21 was not detected and p53, p16, and Rb expression was not altered by SIRT6
depletion (Fig 3D).
Expression of genes involved in nucleosome assembly is significantly
altered in SIRT6-depleted Hep3B cells
To identify the mediating effectors contributing to the induction of cellular senescence by
SIRT6 depletion, microarray analysis was performed in control and SIRT6-depleted Hep3B
cells. Expression of SIRT6 was down-regulated in SIRT6 depleted Hep3B cells by ~50% in our
dataset (GEO database, accession number: GSE75905). The cellular processes affected by
SIRT6 depletion were systematically characterized using gene ontology (GO) analysis. Differ-
entially expressed genes most enriched in response to SIRT6 depletion were associated with
nucleosome assembly which includes histone variant genes (Fig 4A). Genes encoding histone
variants were significantly downregulated (Fig 4B). Changes in gene expression, including
HIST2H2AA4, HIST2H2BE, HIST1H2AC, HIST1H1C, and HIST1H2BK, were further vali-
dated by RT-PCR. The mRNA levels of these genes were significantly decreased by SIRT6
depletion (Fig 4C).
SIRT6 depletion elicits DNA damage and G2/M phase arrest
DNA damage was confirmed by immunofluorescent staining of γ-H2AX (Fig 5A) because
DNA damage was suggested to induce histone loss[24–26]. SIRT6-depleted Hep3B cells had
more γ-H2AX-positive foci than control cells (Fig 5A and 5B). The effect of SIRT6 depletion
on the expression of DNA damage responsive proteins was investigated by western blotting.
The expression of p-chk2Thr68 and p-ATRSer428 was increased in SIRT6-depleted Hep3B cells
(Fig 5C). Additionally, the mRNA levels of many genes involved in the response to DNA dam-
age were significantly changed by SIRT6 depletion, according to microarray and GO analyses
(P = 0.073605). Majority of genes involved in the response to DNA damage were significantly
upregulated (S1 Fig). BecauseDNA damage can affect cell cycle progression[27], FACS analysis
was performed on SIRT6-depleted Hep3B cells. FACS analysis revealed that more SIRT6-de-
pleted cells were arrested in the G2/M phase of the cell cycle than control cells (Fig 5D). Knock-
down of SIRT6 upregulated the expression of cyclin B1 and p-cdc2Tyr15, and downregulated
the expression of cyclin E (Fig 5E). Since an increase in G2/M phase is also characteristic for
proliferating cells, BrdU assay was performed to evaluate the portion of proliferating cells.
Flow cytometry analyses revealed that the portion of BrdU-positive cells decreased in SIRT6--
depleted Hep3B cells (Fig 5F and 5G).
Discussion
In this study, we highlighted the role of SIRT6 which is upregulated in HCC.Mechanistically,
SIRT6 silencing by shRNA induced cellular senescence in the p53/p21- and p16/Rb-pathway
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independentmanners. SIRT6 depletion also caused DNA damage, which could promote both
the downregulation of genes encoding histone variants associated with nucleosome assembly
and cell cycle arrest in the G2/M phase (Fig 6). Our findings demonstrate the oncogenic poten-
tial of SIRT6 in HCC and suggest SIRT6 as a potential therapeutic target for HCC.
SIRT6 was upregulated in HCC tissues and its depletion suppressed the growth of HCC,
supporting its oncogenic potential. Reports on SIRT6 expression in HCC have been controver-
sial and inconsistent. In contrast with our observations, SIRT6 expression was reported to be
lower in HCC tissue than in normal liver tissue based on an analysis of the publically available
Oncomine CancerMicroarray database. In this study, SIRT6 expression was reduced in 45% of
53 human HCCs [14]. However, we demonstrated an upregulation of SIRT6 in HCC cell lines,
and consistently higher levels of SIRT6 were confirmed in HCC specimens. Our results are
supported by recent observations that SIRT6 was upregulated in 101 paired HCC tissues and
60 paired paraffin-embeddedsections and that this increased SIRT6 expression was associated
with larger tumors and a poorer overall survival rate [15]. We also observed that SIRT6 silenc-
ing inhibited colony formation and anchorage-independentHCC cell growth. Furthermore,
SIRT6-depleted Hep3B cells produced smaller HCC tumors in vivo. Our findings from in vitro
Fig 4. Microarray analysis of SIRT6-depleted Hep3B cells. (A) Microarray data show statistically significant effects of
SIRT6 knockdown on gene expression with the indicated gene ontology. (B) The heat map shows the effect of SIRT6
depletion (from two independent Hep3B cell infections designated as “a” and “b”) on genes that function in nucleosome
assembly. (C) mRNA levels of the selected nucleosome assembly genes in control and SIRT6-depleted Hep3B cells are
indicated in the histogram. All data are representative of two independent experiments.
doi:10.1371/journal.pone.0165835.g004
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Fig 5. Effect of SIRT6 knockdown on DNA damage and cell cycle progression. (A) Expression of γ-H2AX was assessed by
immunocytochemistry using a confocal microscope. (B) Cells with over 10 foci were quantified by counting cells from the randomly
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and in vivo studies, together with the analysis of patient specimens, collectively show that
SIRT6 has oncogenic potential in HCC.
SIRT6 point mutation was reported to occur in several types of cancers[19]. However,
SIRT6 mutations do not seem to naturally and frequently occur in HCC according to the public
databases providing SIRT6 status in HCCs, indicating that SIRT6 can be active in most HCC
and the effect of SIRT6 depletion is mediated by absence of active SIRT6. Discrepancy between
previous reports and data from public databases regarding the status of SIRT6 in HCCmight
be explained by the fact that SIRT6 mutation seems to occur in tissue-dependentmanners.
Kugel et al. showed that SIRT6 mutations were found in tumor types such as non-small-cell
lung cancer, renal clear cell carcinoma, cervical carcinoma, and melanoma[19], but not in
HCC.
obtained images. The quantified cells were compared in the histogram. The scale bar indicates 30 μM. (C) The expression of indicated
proteins was assessed by western blotting. Cells for western blotting and immunocytochemistry were harvested or fixed 5 days after
viral transduction. (D) Propidium iodide staining was performed to determine the cell cycle distribution in Hep3B cells 5 days after
infection with lentiviruses containing NC or shSIRT6. The numbers of Hep3B cells at the G1, S, and G2/M phases were quantified by
FACS analysis. The Modifit program was used for data analysis. (E) Expression of cell cycle-related proteins and SIRT6 were assessed
by western blotting. Cells for microarray, RT-PCR, and western blotting were harvested 5 days after viral transduction. All data are
representative of three independent experiments. (F) Representative FACS analysis of BrdU incorporation. (G) Cell proliferation rate of
NC and shSIRT6-depleted cells as quantified by FACS analysis of four independently performed experiments. (**P<0.01, *P<0.05).
doi:10.1371/journal.pone.0165835.g005
Fig 6. Schematic diagram of SIRT6 depletion in HCC. SIRT6 depletion eventually leads to cellular senescence via the
induction of DNA damage, which causes G2/M phase arrest and downregulation of genes encoding histone variants.
doi:10.1371/journal.pone.0165835.g006
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SIRT6 depletion suppressed the growth of HCC by promoting cellular senescence and DNA
damage in the present study. A previous report has shown that SIRT6 depletion suppressed
HCC cell growth and promoted cellular apoptosis by upregulating Bax expression[15]. In
agreement with these findings, we also confirmed that some of SIRT6-depleted cells were
undergone apoptosis as judged by the Hoechst staining (S2 Fig). Senescence and apoptosis
pathways are simultaneously involved in stress responses including DNA damage, and it is the
particularwiring of each cell type that decides whether senescence or apoptosis will occur first
[28]. In some conditions, apoptosis is the consequence of overwhelming stress, whereas senes-
cence is a response to less severe damage[28]. Indeed, a mixture of apoptosis and senescence
was reported in human diploid fibroblasts exposed to cellular stress[29]. Uneven silencing of
SIRT6 by shRNA among cells would reflect different degrees of SIRT6 downregulation, which
might induce different levels of DNA damage. These differences could explain the different
phenotypes, such as apoptosis and senescence, observed in HCC cells.
Acute cellular senescence is one of mechanisms to restrain proliferation of potentially
tumorigenic cells[23, 28]. SIRT6 silencing suppressed HCC cell growth by induction of cellular
senescence. Consistent with our finding, SIRT6 depletion was reported to induce cellular senes-
cence in several model cell lines. However, most studies on the inhibitory role of SIRT6 in
senescencewere performed using non-tumorigenic cell lines such as bronchial epithelial cells
[30, 31], human fibroblast[32], endothelial cell[33, 34], chondrocyte[35] and keratinocyte[36]
in the points of anti-aging effects of SIRT6. In this report, inhibitory roles of SIRT6 in senes-
cence were investigated using tumorigenic cell lines in a normal condition. Though a group
recently reported the inhibitory role of SIRT6 in senescence using HCC cell lines, they per-
formed all experiments under the treatment of TGF-1β/H2O2/HOCI which could induce cellu-
lar senescence[37]. In this context, senescencewas induced by activating the classical p16 and
p21 pathways[37]. However, our results indicated that SIRT6 depletion without the treatment
of TGF-1β/H2O2/HOCI promoted cellular senescence in the p16/Rb- and p53/p21-indepen-
dent manners. As Hep3B cells do not express p53 and Rb, and p53 is mutated in Huh-7 cells
[16], Rb, p53, and p21 expression was not detected in Hep3B cells and p53, p21, p16, and Rb
expression was not affected by SIRT6 depletion in Huh-7 cells. Because senescence is fre-
quently associated with DNA damage, the observed senescence could represent a cellular
response to DNA damage caused by the loss of SIRT6. In the present study, the loss of SIRT6
increasedDNA damage and increased the expression of p-ATRSer428 and p-chk2Thr68. The ser-
ine/threonine protein kinases ATM and ATR were activated as a part of the genotoxic stress
response and phosphorylated chk2, chk1, and H2AX[38]. The induction of DNA damage by
SIRT6 silencing could be supported by several studies investigating SIRT6-mediated DNA
repair. SIRT6 promotes DNA DSB repair by stabilizing the DNA-PK catalytic subunit (a DSB
repair factor) in the chromatin adjacent to DSB[39] or by deacetylating the C-terminal binding
protein interacting protein crucial in DSB repair[40]. SIRT6 also contributes to DSB repair by
stimulating the poly-ADP-ribosylase activity of poly[ADP-ribose] polymerase 1 in response to
DNA damage[41]. Thus, DNA damage may not be repaired properly in SIRT6-depleted cells
because SIRT6 promotes DNA repair. Taken together, these findings demonstrated that SIRT6
depletion increasedDNA damage, causing subsequent DNA damage responses and eventual
cellular senescence in HCC.
In consistent with the previous reports that DNA damage is linked to altered cell cycle dis-
tribution[27] and histone loss[25, 26], our expression and cell cycle analyses showed that
SIRT6 depletion downregulated histone-encoding genes and promoted altered cell cycle distri-
bution. Change of the chromatin structure by downregulated histone levels could be a cause of
cellular senescence[24].Downregulation of histone levels caused chromatin to be more open,
which led to inappropriate access to DNA, disrupting transcriptional regulation and chromatin
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destabilization[24, 25]. Maintenance of the fundamental chromatin structure was reported to
be important for delaying the aging process and overexpression of histones extends life span
[42]. Thus, histone loss in SIRT6-deficient cells might accelerate cellular senescence by chro-
matin destabilization. Usually, cyclin B1 reaches maximum level at G2/M phase and cyclin E
does at G1/S transition and its level is relatively low at G2/M phase[43]. The accumulation of
p-cdc2Tyr15, an inactive form of cdc2, which regulates the G2/M phase transition, could also be
an indicator of halted G2/M phase transition[27]. SIRT6 silencing upregulated cyclin B1 and
p-cdc2Tyr15 expression, and downregulated cyclin E expression. In addition, portion of Brdu-
positive cells which were proliferating decreased among SIRT6-depleted cells, indicating that
SIRT6-depleted cells were arrested in the G2/M phase. Because G2/M arrest is a common
checkpoint mechanism in response to DNA damage[27], it is very likely that the G2/M arrest
we observedwas initiated by DNA damage caused by SIRT6 depletion. In addition, cancer cell
with a defective G1 checkpoint resulted in more profound G2/M arrest upon DNA damage
[27] and Hep3B do not express Rb proteins that regulate the G1/S transition[16]. In summary,
cellular senescence in SIRT6-depeleted HCC cells was induced by DNA damage, which might
downregulate histone-encoding genes associated with nucleosome assembly and promote G2/
M arrest.
In summary, we have demonstrated that SIRT6 plays an oncogenic role in HCC. Our find-
ings showed that SIRT6 depletion inhibited tumor growth by inducing cellular senescence via a
p16/Rb- and p53/p21- independent pathway. SIRT6 depletion arrested the cell cycle in the G2/
M phase and downregulated histone variants associated with nucleosome assembly, which was
attributed to DNA damage (Fig 6). Taken together, our findings suggest that SIRT6 acts as a
tumor promoter by preventing DNA damage and cellular senescence, indicating that SIRT6
represents a potential therapeutic target for the treatment of HCC.
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